[go: up one dir, main page]

TR200806646A2 - Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar - Google Patents

Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar

Info

Publication number
TR200806646A2
TR200806646A2 TR2008/06646A TR200806646A TR200806646A2 TR 200806646 A2 TR200806646 A2 TR 200806646A2 TR 2008/06646 A TR2008/06646 A TR 2008/06646A TR 200806646 A TR200806646 A TR 200806646A TR 200806646 A2 TR200806646 A2 TR 200806646A2
Authority
TR
Turkey
Prior art keywords
levodopa
entacapone
pharmaceutical combinations
carbidoba
combinations including
Prior art date
Application number
TR2008/06646A
Other languages
English (en)
Inventor
Ebrahi̇mi̇ Şi̇ri̇n
Badem Gülhan
Ağcayazi Mehmet
Original Assignee
Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. filed Critical Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş.
Priority to TR2008/06646A priority Critical patent/TR200806646A2/tr
Publication of TR200806646A2 publication Critical patent/TR200806646A2/tr
Priority to PCT/TR2009/000112 priority patent/WO2010027340A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Buluş entakapon, levodopa ve karbodiba içeren farmasötik kombinasyonlarla ilgili olup, özelliği; entakapon, levodopa ve karbidopa veya bu moleküllerin kabul edilebilir tuz, sulu formları veya fizikokimyasal açıdan her türlü polimorflarını içeren, farmasötik olarak stabil kompozisyonlarının Parkinson Hastalığı tedavisine yönelik olarak hazırlanmasına dair kompozisyonlar ve bu kompozisyonların hazırlanışını kapsamasıdır.
TR2008/06646A 2008-09-03 2008-09-03 Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar TR200806646A2 (tr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2008/06646A TR200806646A2 (tr) 2008-09-03 2008-09-03 Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
PCT/TR2009/000112 WO2010027340A1 (en) 2008-09-03 2009-09-03 Pharmaceutical compositions composing entakapon, levodopa and karbidoba

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2008/06646A TR200806646A2 (tr) 2008-09-03 2008-09-03 Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar

Publications (1)

Publication Number Publication Date
TR200806646A2 true TR200806646A2 (tr) 2009-06-22

Family

ID=41314610

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2008/06646A TR200806646A2 (tr) 2008-09-03 2008-09-03 Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar

Country Status (2)

Country Link
TR (1) TR200806646A2 (tr)
WO (1) WO2010027340A1 (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2614179T3 (es) 2010-03-04 2017-05-30 Orion Corporation Uso de levodopa, carbidopa y entacapona para el tratamiento de la enfermedad de Parkinson
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
SG10201911731YA (en) * 2013-03-13 2020-02-27 Neuroderm Ltd Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20060173074A1 (en) * 2004-11-10 2006-08-03 Juha Ellmen Treatment of restless legs syndrome
US20060222703A1 (en) * 2005-04-01 2006-10-05 Iprbox Oy Pharmaceutical composition and preparation method thereof
SI1896006T1 (sl) * 2005-06-08 2010-02-26 Orion Corp Postopek za izdelavo granul, ki vsebujejo entakapon, za oralne odmerne oblike
EP2104424A4 (en) * 2006-10-30 2011-06-15 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA
JP5466179B2 (ja) * 2008-02-06 2014-04-09 ウォックハート リサーチ センター 生物学的利用能が改善されたエンタカポン、レボドパ及びカルビドパの医薬組成物

Also Published As

Publication number Publication date
WO2010027340A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
EA200970287A1 (ru) Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
TN2011000209A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
CY1118374T1 (el) ΣΥΝ-ΚΡΥΣΤΑΛΛΟΙ ΤΡΑΜΑΔΟΛΗΣ KAI NSAIDs
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
WO2007095050A3 (en) N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
TW200730515A (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EA201370208A1 (ru) Формы рифаксимина и их применение
WO2008130320A3 (en) Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
UA98961C2 (uk) Похідні піразинону та їх застосування у лікуванні легеневих захворювань
MY142067A (en) Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
BRPI0820668A2 (pt) Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
TR200806646A2 (tr) Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
MX2011011490A (es) Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos.